CHICAGO, June 20, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases, announced today that it will participate in... read more →
VQ-101 is a potent allosteric activator of glucocerebrosidase (GCase) The Phase 1 program aims to demonstrate VQ-101’s pharmacodynamic effects in healthy volunteers and Parkinson’s patients CHICAGO, April 09, 2024 (GLOBE... read more →
February 27, 2024 07:30 ET (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders,... read more →
CHICAGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that its development candidate VQ-101, a best-in-class brain-penetrant small molecule allosteric activator of glucocerebrosidase (GCase), will enter clinical development in the... read more →
CHICAGO, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company focused on discovering and developing next-generation medicines that have the potential to transform the lives of patients with... read more →
CHICAGO, March 22, 2023 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company focused on discovering and developing next-generation medicines that have the potential to transform the lives of patients with neurodegenerative... read more →
Tune in to hear John Flavin and the Chicago Biomedical Consortium Entrepreneurial Fellows engage with Jim, aiming to learn more about the life sciences industry and the different means of... read more →
Dr. Sullivan and Biotech 2050 Podcast host Alok Tayi discuss Vanqua Bio’s platform, lead programs, and our focus on Parkinson's disease. Tune in...
Vanqua Bio today announced that the company will participate in the Stifel 2022 CNS Day Conference, which is being held virtually March 28-29. “Vanqua Bio was founded to transform a cutting-edge... read more →
– Novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to enable next-generation therapies – – Lead program targets Parkinson's disease and all forms of... read more →